In this study, most patients with WFS1-DM required insulin treatment and lacked the clinical features of insulin resistance, and the serum C-peptide level in carriers with rare and predicted deleterious variants was lower than that in the EOD group without rare variants. The gene discussed is INS; the disease is diabetes mellitus.